Method for producing high-purity vascular endothelial cell population from biological tissue or organ
The method for producing a highly purified vascular endothelial cell population using a culture system with a porous membrane addresses the limitations of current therapeutic angiogenesis methods by achieving long-term blood vessel regeneration and improved vascular disease treatment through a high-purity vascular endothelial cell population with significant angiogenic potential.
Patent Information
- Application Number
- PCT/JP2024/017958
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-15
- Filing Date
- 2024-05-15
- Publication Date
- 2024-11-21
AI Technical Summary
Current methods for therapeutic angiogenesis, such as cell therapy and cytokine therapy, face limitations in long-term maintenance of blood vessel regeneration and effectiveness in patients with weakened vascular regeneration ability, as vascular endothelial progenitor cells are not stem cells and have limited long-term contributions, and cytokine therapies have limited effects.
A method for producing a highly purified vascular endothelial cell population from living tissues or organs using a culture system with a porous membrane, where the culture medium from two vessels is passed through a porous membrane, allowing cell migration and collection, with extracellular matrix containing vascular endothelial cell migration factors, to achieve a high purity and angiogenic potential.
The method achieves a vascular endothelial cell population with a purity of 50% or more, containing vascular endothelial stem cells that can regenerate blood vessels, improve ischemia, and promote organ regeneration, effectively treating vascular diseases and abnormalities.
Smart Images

Figure 000028 
Figure 000029 
Figure 000030
Abstract
Description
Method for producing a highly purified vascular endothelial cell population from biological tissue or organ
[0001] The present invention relates to a method for producing a highly purified vascular endothelial cell population from biological tissue or organ, a method for determining the angiogenic ability of a vascular endothelial cell population, a method for purifying vascular endothelial cells, a method for growing vascular endothelial cells from biological tissue or organ, and a method for producing a vascular endothelial cell sheet.
[0002] Angiogenesis is induced by two major processes. During fetal development, endothelial cells differentiated from mesodermal tissue form vascular cavities and construct new blood vessels in avascular regions, a process known as vasculogenesis. After birth, a fine vascular network is already established within the body. When new blood vessels are needed due to ischemia or malnutrition, new blood vessels sprout from existing vessels and grow from them, a process known as angiogenesis. Vascular diseases, including malignant tumors, retinopathies, chronic inflammatory diseases, arteriosclerosis, ischemic diseases, diabetes, and autoimmune diseases, are collectively known as vascular diseases. Therapeutic angiogenesis, which aims to improve these diseases by controlling angiogenesis, is a key therapeutic approach. This approach aims to improve the pathology of diseases with reduced blood vessel numbers or impaired vascular function due to various causes. For example, there are methods for improving ulcers by regenerating blood vessels in ischemic diseases (such as lower limb ischemia and myocardial ischemia) caused by arteriosclerosis and thrombosis, and intractable skin necrosis observed in patients with diabetes or autoimmune diseases.
[0003] The effectiveness of therapeutic vascular regeneration for the above-mentioned diseases is being demonstrated in basic medical studies using animal models. In actual clinical practice, cell therapy and cytokine (gene) therapy have been applied. For example, one cell therapy method is to regenerate blood vessels using endothelial progenitor cells present in bone marrow. However, because endothelial progenitor cells are not stem cells, the formed blood vessels do not persist for long periods. Furthermore, the effectiveness of therapies that administer cytokines (or their genes) that induce angiogenesis is extremely limited, even when used in patients whose vascular regeneration ability is already impaired.
[0004] The present inventors have discovered that vascular endothelial stem cells (VESCs), which exhibit stem cell properties such as the ability to contribute long-term to the vascular supply of transplanted organs, exist in the existing blood vessels of various organs in the body. They have successfully defined these VESCs as CD31 (a pan-endothelial cell marker) positive, CD45 (a pan-blood cell marker) negative, CD200 positive, and CD157 positive cells (Non-Patent Document 1). They have discovered that using these VESCs can improve ischemia in ischemic diseases for the long term, reconstruct hepatic sinusoidal vessels, and completely cure hemophilia by secreting coagulation factor VIII from the reconstructed sinusoidal vessels (Patent Document 1). Furthermore, they have discovered that these VESCs can be engineered to secrete transfected molecules for the long term in vivo, and have invented a cell therapy method that functions as a new in vivo drug manufacturing factory for the treatment of cancer, metabolic diseases, and other conditions (Patent Document 1). Furthermore, the present inventors have discovered a method for reprogramming human umbilical vein endothelial cells to a VESC-like phenotype using an extract of mouse liver tissue immediately after birth (Patent Document 2).
[0005] WO2019 / 098264WO2021 / 070874
[0006] Wakabayashi T. et al., CD157 Marks Tissue-Resident Endothelial Stem Cells with Homeostatic and Regenerative Properties, Cell Stem Cell, 2018; 22(3):384-397.
[0007] The present invention aims to provide a method for producing a highly purified vascular endothelial cell population from biological tissue or organ, and a pharmaceutical containing the produced vascular endothelial cell population as an active ingredient. Furthermore, the present invention aims to provide a method for determining the angiogenic potential of a vascular endothelial cell population, a method for purifying vascular endothelial cells, a method for growing vascular endothelial cells from biological tissue or organ, and a method for producing a vascular endothelial cell sheet.
[0008] In order to solve the above-mentioned problems, the present invention encompasses the following inventions. [1] A method for producing a vascular endothelial cell population from a biological tissue or organ, comprising using a culture vessel configured such that a medium in a first culture vessel and a medium in a second culture vessel are in contact with each other via a porous membrane having pores for cell permeation, the culture surface of the first culture vessel being coated with an extracellular matrix containing a vascular endothelial cell migration factor, filling the first and second culture vessels with medium, initiating culture of the biological tissue or organ in the second culture vessel, and recovering cells that have permeated the porous membrane and migrated into the first culture vessel. [2] The method according to [1] above, wherein the purity of the vascular endothelial cells in the vascular endothelial cell population is 50% or more. [3] The method according to [1] or [2] above, wherein the proportion of CD157-positive cells among the vascular endothelial cells in the vascular endothelial cell population is 5% or more. [4] The method according to any of [1] to [3] above, wherein the porous membrane is formed from a biocompatible material. [5] The method according to [4] above, wherein the biocompatible material is selected from the group consisting of collagen, fibrin, hyaluronic acid, polylactic acid, polyglycolic acid, polycaprolactone, polydioxanone, trimethylene carbonate, polyethylene glycol, alginate, chitosan, and mixtures thereof. [6] The method according to any one of [1] to [5] above, wherein the vascular endothelial cell migration factor is one or more selected from the group consisting of vascular endothelial growth factor, basic fibroblast growth factor, hepatocyte growth factor, epidermal growth factor, SDF-1, granulocyte-colony stimulating factor, leukemia inhibitory factor, nerve growth factor, platelet-derived growth factor, stem cell growth factor, axon repulsive factor, granulocyte-macrophage colony-stimulating factor, sphingosine-1-phosphate, angiopoietin, interleukin, CCL5, CCL1, placenta growth factor, apelin, elabella, netrin, semaphorin, gremlin, BafA, and serum. [7] The method according to any one of [1] to [6] above, wherein the extracellular matrix is one or more selected from the group consisting of basement membrane matrix, laminin, type I collagen, type IV collagen, fibronectin, vitronectin, fibrin, tenascin, hyaluronic acid, and proteoglycan.[8] A pharmaceutical comprising, as an active ingredient, a vascular endothelial cell population produced by the method according to any one of [1] to [7] above. [9] The pharmaceutical according to [8] above, which is for vascular regeneration, ameliorating ischemia, ameliorating malnutrition, treating vascular malformations, ameliorating blood flow insufficiency caused by vascular malformations, promoting organ regeneration, or treating diseases caused by abnormalities in molecules secreted by vascular endothelial cells.
[10] A method for determining the angiogenic potential of a vascular endothelial cell population produced by the method according to any one of [1] to [7] above, comprising: placing a second culture vessel having the porous membrane on its bottom surface on top of a first culture vessel to initiate culture; observing the cells on the bottom surface of the lower culture vessel of the first culture vessel after the initiation of culture; and determining that the obtained vascular endothelial cell population has angiogenic potential if a vascular network is formed.
[11] A method for purifying vascular endothelial cells from biological tissue or organs, comprising using a culture vessel having a structure in which a medium in a first culture vessel and a medium in a second culture vessel are in contact with each other via a porous membrane having pores for cell permeation, the culture surface of the first culture vessel being coated with an extracellular matrix containing a vascular endothelial cell migration factor, filling the first and second culture vessels with medium, initiating culture of the biological tissue or organ in the second culture vessel, and recovering the cells that have permeated the porous membrane and migrated into the first culture vessel.
[12] The method according to
[11] above, wherein the purity of vascular endothelial cells among the recovered cells is 50% or more.
[13] A method for growing vascular endothelial cells of a biological tissue or organ, comprising using a culture vessel having a structure in which a culture medium in a first culture vessel and a culture medium in a second culture vessel are in contact with each other via a porous membrane having pores for cell permeation, the culture surface of the first culture vessel being coated with an extracellular matrix containing a vascular endothelial cell migration factor, filling the first and second culture vessels with culture medium, and culturing the biological tissue or organ in the second culture vessel.
[14] A method for producing a vascular endothelial cell sheet, comprising using a culture vessel having a structure in which a medium in a first culture vessel and a medium in a second culture vessel are in contact with each other via a porous membrane having pores for cell permeation, the culture surface of the first culture vessel being coated with an extracellular matrix containing a vascular endothelial cell migration factor, filling the first and second culture vessels with medium, initiating the culture of a biological tissue or organ in the second culture vessel, recovering the porous membrane, and removing the cells and tissue or organ present on the porous membrane on the second culture vessel side.
[15] The method according to
[14] above, wherein the porous membrane is formed from a biocompatible material.
[0009] The present invention provides a method for producing a highly purified vascular endothelial cell population from biological tissue or organs, and a pharmaceutical containing the produced vascular endothelial cell population as an active ingredient. The present invention also provides a method for determining the angiogenic potential of a vascular endothelial cell population, a method for purifying vascular endothelial cells, a method for growing vascular endothelial cells from biological tissue or organs, and a method for producing a vascular endothelial cell sheet.
[0010]
[0033] Figure 1 shows the experimental procedure of Example 1. (A) is a representative image of cells adhered to the underside of the porous membrane (polycarbonate membrane) of an upper culture vessel (Transwell insert) immunostained with an anti-CD31 antibody, and (B) is a representative image of cells on a basement membrane matrix coated on the bottom of the well.
[0034] Figure 1 shows the results of flow cytometry analysis of cells before and after culture, stained with anti-CD31, anti-CD45, and anti-CD157 antibodies for surface antigens. (A) shows the results for cells obtained by dispersing adipose tissue before the start of culture, (B) shows the results for cells recovered from the underside of the porous membrane on day 14 of culture, and (C) shows the results for cells recovered from the basement membrane matrix on day 14 of culture.
[0035] Figure 1 shows the experimental procedure of Comparative Example 1.
[0036] Figure 1 shows representative images of vascular endothelial cells isolated from human adipose tissue and human mesenchymal stem cells co-cultured for 10 days and immunostained with an anti-CD31 antibody.
[0037] Figure 2 shows the experimental procedure of Comparative Example 2. This figure shows representative images and enlarged images of cells that grew and proliferated from minced human adipose tissue after 21 days of culture and immunostained with anti-CD31 antibody. Minced human adipose tissue was cultured for 21 days, and cells that grew and proliferated from the adipose tissue were collected by mechanical and enzymatic dispersion. Surface antigen staining with anti-CD44 antibody or anti-CD31 and anti-CD45 antibodies was performed on the cells, followed by flow cytometry analysis. (A) shows the results of analyzing the percentage of CD44-positive cells (mesenchymal cells), and (B) shows the results of analyzing the percentage of CD31-positive, CD45-negative cells (vascular endothelial cells). This figure shows the results of confirming the wound healing effect of a vascular endothelial cell sheet. (A) is an image of the back of a nude mouse immediately after skin removal and 7 days after application of a vascular endothelial cell sheet, and (B) shows the recovery rate of the skin injury site. 1 shows the results of histological observation of the vascular endothelial cell sheet-applied site, with (A) the result for a control mouse and (B) the result for a mouse with a vascular endothelial cell sheet applied. Figure 1 shows representative images of cells adhered to the underside of the collagen membrane of the upper culture vessel (cell strainer) immunostained with an anti-CD31 antibody.
[0011] [Method for producing a vascular endothelial cell population] The present invention provides a method for producing a vascular endothelial cell population from a biological tissue or organ (hereinafter referred to as the "production method of the present invention"). The production method of the present invention makes it possible to produce a highly pure vascular endothelial cell population from a biological tissue or organ.
[0012] The biological tissue or organ used in the production method of the present invention is not particularly limited as long as it contains vascular endothelial cells, and examples thereof include placenta, umbilical cord, skin, liver, lung, brain, kidney, omentum, muscle, intestinal mucosa, gastric mucosa, and adipose tissue.
[0013] The production method of the present invention can be carried out using a culture vessel having a structure in which the medium in the first culture vessel and the medium in the second culture vessel can come into contact with each other via a porous membrane having pores for cell permeation. Examples of culture vessels having such a structure include, but are not limited to, a culture vessel in which a second culture vessel having a porous membrane on the bottom surface is placed inside a first culture vessel (see, for example, FIG. 1).
[0014] When using a culture vessel in which a second culture vessel with a porous membrane on the bottom surface is placed within a first culture vessel, the first culture vessel can be a cell culture dish, a cell culture multiwell plate, or the like. The size of the culture vessel is not particularly limited and can be selected appropriately depending on the number of cells in the vascular endothelial cell population to be produced. The second culture vessel is not particularly limited as long as it can be placed within the first culture vessel and has a porous membrane on the bottom surface. It can be a commercially available product or a homemade product. Examples of commercially available products include Transwell® Transwell Permeable Support (Corning), TC Insert (SARSTEDT), and Millicell® Cell Culture Insert (MILLIPORE). Homemade products include commercially available cell strainers with the mesh removed and any porous membrane attached to the bottom.
[0015] The material of the porous membrane is not particularly limited as long as it can be used for cell culture. For example, polycarbonate, polyester (PET), polytetrafluoroethylene, polysulfone, polypropylene, polyvinylidene fluoride, polyamide, etc. can be used. The porous membrane may be formed from a biocompatible material. The biocompatible material is not particularly limited, but examples include collagen, fibrin, hyaluronic acid, polylactic acid, polyglycolic acid, polycaprolactone, polydioxanone, trimethylene carbonate, polyethylene glycol, alginate, chitosan, and mixtures thereof. The pore size of the porous membrane may be any size that allows vascular endothelial cells to pass through. For example, it may be 1 μm or more, 3 μm or more, 5 μm or more, 8 μm or more, 10 μm or more, or 20 μm or less, 15 μm or less, or 12 μm or less.
[0016] The first culture vessel used in the production method of the present invention has a culture surface coated with an extracellular matrix containing a vascular endothelial cell migration factor. The extracellular matrix is not particularly limited, but examples include basement membrane matrix, laminin, type I collagen, type IV collagen, fibronectin, vitronectin, fibrin, tenascin, hyaluronic acid, and proteoglycan. Commercially available basement membrane matrices include "Cultrex Basement Membrane Extract (BME)" manufactured by R&D and "Matrigel Basement Membrane Matrix" manufactured by Corning.
[0017] Examples of vascular endothelial cell migration factors include vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), epidermal growth factor (EGF), SDF-1 (stromal cell-derived factor-1), and granulocyte colony stimulating factor. G-CSF), leukemia inhibitory factor (LIF), nerve growth factor (NGF), platelet-derived growth factor (PDGF), stem cell growth factor (SCF), axonal repulsion factor (Slit), granulocyte-macrophage colony stimulating factor: GM-CSF), sphingosine-1-phosphate: Examples of chemotactic factors include S1P, angiopoietin (ANGPT), interleukin (IL), CCL5 (CC motif chemokine ligand 5, also known as RANTES), CCL1 (CC motif chemokine ligand 1, also known as I-309), placental growth factor (PLGF), apelin, Elabella, netrin, semaphorin, and serum. Agonists of the receptors of the vascular endothelial cell migration factors exemplified above can also be suitably used as vascular endothelial cell migration factors. Examples of VEGF receptor agonists include Gremlin and BafA.
[0018] The amount of vascular endothelial cell migration factor to be added to the extracellular matrix can be appropriately selected depending on the combination of the extracellular matrix and vascular endothelial cell migration factor used. For example, when VEGF is used as the vascular endothelial cell migration factor and a basement membrane matrix is used as the extracellular matrix, the VEGF concentration in the extracellular matrix is preferably 1 ng / mL to 1000 ng / mL.
[0019] The production method of the present invention uses such a culture vessel, fills the first and second culture vessels with medium, initiates the culture of a biological tissue or organ in the second culture vessel, and recovers cells that have migrated through the porous membrane into the first culture vessel. The medium used may be any medium capable of culturing vascular endothelial cells, and any known medium that has been used successfully for culturing vascular endothelial cells may be used. For example, commercially available media such as HuMedia-EB2 manufactured by KURABO, EGM-2MV manufactured by LONZA, and MiraCell EC Culture Medium manufactured by Takara Bio may be used. When the resulting vascular endothelial cell population is to be used for human therapy, it is preferable to use a xeno-free medium.
[0020] The biological tissue or organ to be cultured in the second culture vessel is preferably placed so as to contact the porous membrane. Furthermore, it is preferable to shred the tissue or organ to promote cell growth and proliferation. The size of the shredded tissue block is not particularly limited, but may be, for example, a 1 mm to 10 mm cube. The amount of tissue to be cultured can be appropriately determined taking into account the size of the second culture vessel and the area of the porous membrane.
[0021] The culture was carried out under conditions commonly used for cell culture (e.g., 37°C, 5% CO 2 ) The culture period is not particularly limited. The time to end the culture is preferably determined by observing the state of the cells that have penetrated the porous membrane and adhered to the porous membrane surface on the first culture vessel side and / or the state of the cells on the culture surface of the first culture vessel. As the state of the cells, colony formation and angiogenesis are preferably observed.
[0022] The method for recovering the cells migrated into the first culture vessel is not particularly limited. For example, cells adhered to the porous membrane surface on the first culture vessel side and to the culture surface of the first culture vessel can be detached and recovered using a known cell detachment agent. If the recovered cells are CD31-positive cells or CD31-positive CD45-negative cells, they can be determined to be vascular endothelial cells. Furthermore, vascular endothelial stem cells among the recovered cells can be confirmed by the presence of CD31-positive CD157-positive cells or CD31-positive CD45-negative CD157-positive cells.
[0023] The production method of the present invention makes it possible to obtain a vascular endothelial cell population having a vascular endothelial cell purity of 50% or more. The vascular endothelial cell purity may be 60% or more, 70% or more, 80% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more. The production method of the present invention makes it possible to obtain a vascular endothelial cell population having a proportion of vascular endothelial stem cells (CD157-positive cells) among the obtained vascular endothelial cells of 5% or more. The proportion of vascular endothelial stem cells among the vascular endothelial cells may be 6% or more, 7% or more, 8% or more, 9% or more, or 10% or more.
[0024] The vascular endothelial cell population obtained by the production method of the present invention significantly improves the vascular endothelial cell content in the biological tissue or organ subjected to the production method of the present invention, thereby increasing the number of vascular endothelial cells. Therefore, the present invention provides a method for purifying vascular endothelial cells from biological tissue or organ. The present invention also provides a method for proliferating vascular endothelial cells in biological tissue or organ.
[0025] [Medicine] The present invention provides a pharmaceutical containing, as an active ingredient, a vascular endothelial cell population produced by the production method of the present invention. The pharmaceutical of the present invention can be used for purposes such as vascular regeneration, amelioration of ischemia, amelioration of malnutrition, treatment of vascular malformation, amelioration of blood flow insufficiency caused by vascular malformation, promotion of organ regeneration, and treatment of diseases caused by abnormalities in molecules secreted by vascular endothelial cells.
[0026] The vascular endothelial cell population of the present invention contains vascular endothelial stem cells. The inventors have confirmed that transplantation of vascular endothelial stem cells into the liver of a mouse model of hepatic vascular disorder results in vascular regeneration (see, for example, Patent Document 1). Therefore, the pharmaceutical of the present invention can be suitably used as a pharmaceutical for vascular regeneration. The pharmaceutical of the present invention can ameliorate ischemia and malnutrition caused by impaired vascular function by regenerating blood vessels. Therefore, the pharmaceutical of the present invention is effective in treating ischemic diseases such as cerebral infarction, myocardial infarction, and Buerger's disease. These ischemic diseases may be caused by arterial diseases such as arteriosclerosis, thrombosis, and arteritis, or lifestyle-related diseases such as hyperlipidemia, diabetes, hypertension, gout, and aging. Furthermore, the pharmaceutical of the present invention can be suitably used for treating vascular malformations or blood flow insufficiency caused by vascular malformations. Vascular malformations include arteriovenous fistulas and moyamoya disease. Furthermore, the pharmaceutical of the present invention can also be used for wound healing.
[0027] The vascular endothelial cell population of the present invention contains vascular endothelial stem cells. The inventors have confirmed that transplantation of vascular endothelial stem cells into the livers of mice undergoing 70% partial hepatectomy promotes liver regeneration (see, for example, Patent Document 1). Therefore, the pharmaceutical of the present invention can be used to promote organ regeneration. The target organ is not particularly limited; the pharmaceutical of the present invention can promote regeneration of any organ as long as vascular regeneration is possible. It has been shown that organ-specific cells (including stem cells) in all organs are induced to survive and proliferate long-term by humoral factors and adhesion factors secreted by vascular endothelial cells. Therefore, regeneration of the organ's blood vessels promotes regeneration of the organ. Therefore, the pharmaceutical of the present invention can treat diseases that are improved by organ regeneration. For example, promoting liver regeneration can prevent or treat liver cirrhosis, hepatic fibrosis, hepatitis, fatty liver, liver failure, etc. The same applies to other organs.
[0028] The vascular endothelial cell population of the present invention includes vascular endothelial stem cells, and the inventors have confirmed that administering the cell population of the present invention prepared from the liver of a mouse having a normal coagulation factor VIII gene to the liver of a hemophilia A model mouse significantly shortened the time from bleeding to hemostasis (see, for example, Patent Document 1). Therefore, the pharmaceutical of the present invention can be used to treat diseases caused by abnormalities in molecules secreted from vascular endothelial cells. Diseases caused by abnormalities in molecules secreted from vascular endothelial cells include, for example, hemophilia A (coagulation factor VIII), hemophilia B (coagulation factor IX), lysosomal storage diseases (α-galactosidase), von Willebrand disease (von Willebrand factor), hypertension (nitric oxide, etc.), impaired glucose tolerance (nitric oxide, etc.), dyslipidemia (nitric oxide, etc.), metabolic syndrome (apelin, etc.), and osteoporosis (Notch ligand, netrin, endothelin-1, etc.) (the molecules secreted from vascular endothelial cells are indicated in parentheses).
[0029] The pharmaceutical of the present invention can be administered to a living body in the form of a cell suspension in which the vascular endothelial cell population of the present invention is suspended in an appropriate solution that can be administered to a living body. Examples of solutions that can be administered to a living body include physiological saline, phosphate-buffered saline (PBS), and other physiological salt solutions. The vascular endothelial cell population of the present invention is usually prepared immediately before administration, but it may also be prepared at the time of use using a cryopreserved vascular endothelial cell population. The pharmaceutical of the present invention can be administered by administering the vascular endothelial cell population of the present invention directly to the target organ for revascularization, or intravenously upstream of the target organ for revascularization. The dosage cannot be determined unambiguously because it varies depending on the target organ for revascularization, the patient's age, weight, etc., but an appropriate dosage can be determined by a physician's judgment taking the above-mentioned circumstances into consideration. For example, 1 to 1 x 10 cells per administration 9 The cells may be administered. The frequency of administration can be appropriately selected from the range of once per day to once per week. The dosage and frequency of administration can be increased or decreased as appropriate depending on the patient.
[0030] [Method for assessing the angiogenic potential of a vascular endothelial cell population] The present invention provides a method for assessing the angiogenic potential of a vascular endothelial cell population produced by the above-described production method of the present invention. The inventors have performed the production method of the present invention by placing a second culture vessel having the porous membrane on its bottom surface on top of a first culture vessel, and have confirmed that when vascular endothelial cells form colonies on the porous membrane surface on the first culture vessel side (the underside of the porous membrane), a vascular network structure is observed on the bottom surface of the first culture vessel (on the coated basement membrane matrix) (see Example 1 of the present application). Therefore, when the production method of the present invention is performed by placing a second culture vessel having the porous membrane on its bottom surface on top of a first culture vessel, if a vascular network is formed by observing the cells on the bottom surface of the first culture vessel after the start of culture, the obtained vascular endothelial cell population can be assessed as having angiogenic potential.
[0031] [Method for producing a vascular endothelial cell sheet] The present invention provides a method for producing a vascular endothelial cell sheet. The method for producing a vascular endothelial cell sheet of the present invention can be carried out by recovering the porous membrane and removing the cells and tissues or organs present on the porous membrane on the second culture vessel side, instead of recovering the cells in the first culture vessel after the start of culture in the above-mentioned production method of the present invention. Since vascular endothelial cells that have permeated the porous membrane are adhered to the surface of the porous membrane on the first culture vessel side, the porous membrane can be used as a vascular endothelial cell sheet as is.
[0032] The porous membrane is preferably made of a biocompatible material, which is not particularly limited, but includes, for example, collagen, fibrin, hyaluronic acid, polylactic acid, polyglycolic acid, polycaprolactone, polydioxanone, trimethylene carbonate, polyethylene glycol, alginate, chitosan, and mixtures thereof.
[0033] The vascular endothelial cell sheet produced by the method for producing a vascular endothelial cell sheet of the present invention can be applied to a damaged area of the skin and used to repair the skin injury. Furthermore, the vascular endothelial cell sheet can be applied to an ischemic area to improve diseases that develop or become more severe due to ischemia. The application site is not limited as long as it is an ischemic area. For example, the sheet can be applied to the brain for cerebral ischemia, the heart for myocardial ischemia, or around the blood vessels of the lower limbs for lower limb ischemia. Furthermore, the vascular endothelial cell sheet can be applied to an area of vascular damage or abnormal blood vessels to improve diseases that develop or become more severe due to vascular damage or abnormal blood vessels.
[0034] Diseases that can be improved by vascular endothelial cell sheets include, but are not limited to, dementia / Alzheimer's disease, Moyamoya disease, heart failure, liver fibrosis, liver cirrhosis, scleroderma, diabetic gangrene, autoimmune diseases, interstitial pneumonia, chronic obstructive pulmonary disease, pulmonary hypertension, glomerulonephritis, kidney diseases, radiation sequelae, and malignant tumors.
[0035] The present invention will be described in detail below using examples, but is not limited to these. [Example 1: Organ culture of minced adipose tissue using a porous membrane] 1. Materials and methods (1) Culture of human adipose tissue The procedure for Example 1 is shown in Figure 1. Human adipose tissue obtained by surgery was minced with scissors to prepare cubic minced tissue blocks with sides of approximately 2 mm. The culture vessel used was a 24-well Costar cell culture multiwell plate (manufactured by Corning) with a Transwell insert (manufactured by Corning) equipped with a polycarbonate membrane with a pore size of 8.0 μm. Thawed basement membrane matrix (Cultrex Basement Membrane Extract (BME) from R&D) was supplemented with VEGF (PEPRO TECH) at a final concentration of 400 ng / mL. 250 μL of this solution was dispensed into each well of a 24-well plate and allowed to solidify at 37°C. 250 μL of Hu-Media EG2 (serum-free liquid medium for the growth of normal human vascular endothelial cells, from Kurabo Industries) was then added. Minced adipose tissue was placed on the polycarbonate membrane of a Transwell insert and inserted into each well of the 24-well plate. 80 μL of Hu-Media EG2 was added to the insert, and the cells were cultured at 37°C in 5% CO2. The culture medium was replaced on days 6 and 12. On day 14 of culture, the inserts were harvested for immunostaining and flow cytometry analysis.
[0036] (2) Immunostaining of Cells on the Underside of the Membrane and Observation of Cells on the Matrix To detect endothelial cells on the underside of the polycarbonate membrane, the polycarbonate membrane was excised from the insert and fixed with 4% paraformaldehyde. Immunostaining was performed using an anti-CD31 antibody (clone WM59, BioLegend) and color development was performed using diaminobenzidine (DAB, DOJINDO). Cells on the matrix coating on the bottom of the well were observed under a phase-contrast microscope.
[0037] (3) Flow cytometry analysis. For flow cytometry analysis, the polycarbonate membrane was excised from the insert. Adipose tissue and cells on the upper surface of the membrane were removed with a cotton swab. The cells on the lower surface were washed with PBS and then detached and collected using Accutase (Innovative Cell Technologies). Cell surface antigen staining was performed using anti-CD31 antibody (clone WM59, BioLegend), anti-CD45 antibody (clone 2D1, BioLegend), and anti-CD157 antibody (clone RF3, MBL Life Sciences). Analysis was performed using a FACSAria II.
[0038] 2. Results A representative image of stained vascular endothelial cells (CD31-positive cells) on the underside of the polycarbonate membrane is shown in Figure 2(A). On the upper surface of the polycarbonate membrane, mesenchymal cells proliferated from the adipose tissue, as in Comparative Example 2 described below. However, vascular endothelial cells were observed to pass through the pores of the porous membrane due to the concentration gradient of VEGF contained in the basement membrane matrix at the bottom of the well, forming very large colonies measuring approximately 1 cm in diameter on the underside of the porous membrane. These results suggest that vascular endothelial cells are proliferating and are being produced from vascular endothelial stem cells.
[0039] A representative image of cells on the matrix coating on the bottom of the well is shown in Figure 2(B). A vascular network structure was observed on the coated basement membrane matrix, and it was confirmed that vascular endothelial cells that passed through the pores of the porous membrane further migrated into the basement membrane matrix and formed a vascular network on the matrix. Whenever vascular endothelial cells formed colonies on the underside of the porous membrane, a vascular network structure was observed on the matrix below. Therefore, if a vascular network could be confirmed to have been formed on the matrix, it was believed that it could be guaranteed that the cells adhered to the underside of the porous membrane and / or the vascular endothelial cells present in the lower culture vessel were vascular endothelial cells with angiogenic potential.
[0040] The results of flow cytometry analysis are shown in Figure 3. (A) shows the results for cells obtained by dispersing adipose tissue before the start of culture, (B) shows the results for cells recovered from the underside of a porous membrane, and (C) shows the results for cells recovered from a basement membrane matrix. (A) The adipose tissue before the start of culture contained 2.8% CD31-positive endothelial cells, of which only 2.8% were CD157-positive endothelial stem cells. (B) All cells recovered from the underside of a porous membrane were CD31-positive endothelial cells, of which 14.8% were CD157-positive endothelial stem cell fraction. (C) All cells recovered from a basement membrane matrix were also CD31-positive endothelial cells, of which 6.5% were CD157-positive endothelial stem cell fraction. These results demonstrate that the culture method of this example can purify endothelial cells without specific cell fractionation procedures such as fluorescence spectroscopy or magnetic cell sorting. Furthermore, it was revealed that the use of the culture method of this example increases the proportion of vascular endothelial stem cells (CD157 positive) in purified vascular endothelial cells.
[0041] Comparative Example 1: Coculture of Adipose Tissue-Derived Vascular Endothelial Cells and Mesenchymal Stem Cells. 1. Materials and Methods. The procedure for Comparative Example 1 is shown in Figure 4. Human adipose tissue obtained by surgery was minced with scissors. The resulting sludge was treated with a collagenase-based enzyme solution (a solution of 4% fetal bovine serum (FBS) in PBS (4% FBS / PBS) supplemented with 0.2% type I collagenase (Wako), 3 mM CaCl2 (Wako), and 20 μg / mL DNase I (Roche)). The mixture was shaken on a rotator at 37°C for 30 minutes to digest the extracellular matrix. Cells were collected by centrifugation, and red blood cells were lysed using red blood cell lysing buffer (Sigma). After hemolysis, the cells were washed with 4% FBS-containing PBS and collected by centrifugation. The obtained adipose tissue-derived cells were subjected to surface antigen staining using anti-CD31 antibody (clone WM59, BioLegend) and anti-CD45 antibody (clone 2D1, BioLegend), and vascular endothelial cells (CD31 positive, CD45 negative) were isolated by flow cytometry using a FACSAria II (BD).
[0042] Human mesenchymal stem cells (hMSCs, manufactured by Lonza) were used as stromal cells. The mesenchymal stem cells were cultured in a 6-well culture plate (manufactured by Thermo Scientific) until confluent. 2 × 10 isolated adipose tissue-derived vascular endothelial cells were then placed on the plate. 3 Cells were seeded at 100 cells / well and co-cultured in Hu-Media EG2 containing 20 ng / mL VEGF at 37°C in 5% CO2. 60 ng of VEGF was added every 3 days during the culture period. On day 10 of culture, the medium was removed and the cells were fixed with 4% paraformaldehyde. To detect endothelial cells, immunostaining was performed using an anti-CD31 antibody (clone WM59, BioLegend) and color development was performed using diaminobenzidine (DAB, DOJINDO).
[0043] 2. Results Representative images of stained vascular endothelial cells (CD31-positive cells) on day 10 after the start of co-culture are shown in Figure 5. When mesenchymal stem cells were co-cultured as stromal cells, the size of the observed vascular endothelial cell colonies was less than 50 μm in diameter, and no large vascular endothelial cell colonies due to vascular endothelial cell proliferation were observed.
[0044] Comparative Example 2: Detection of Vascular Endothelial Cells by Organ Culture of Minced Adipose Tissue. 1. Materials and Methods. The procedure for Comparative Example 2 is shown in Figure 6. Human adipose tissue obtained by surgery was minced with scissors into cubes approximately 2-6 mm on a side. The slices were placed on 3 cm diameter culture dishes, immersed in Hu-Media EG2, and cultured at 37°C with 5% CO2. Microscopic observations were performed over time. The culture medium was changed every 7 days. On day 21 of culture, the medium was removed, and the tissue and cells on the culture dishes were fixed with 4% paraformaldehyde. To detect vascular endothelial cells, immunostaining was performed using an anti-CD31 antibody (clone WM59, BioLegend) and color development was performed using diaminobenzidine (DAB, DOJINDO). Separately, live cells were collected from other culture dishes by mechanical and enzymatic dispersion and surface antigen staining was performed using anti-CD31 antibody (clone WM59, BioLegend), anti-CD45 antibody (clone 2D1, BioLegend), and anti-CD44 antibody (clone BJ18, BioLegend), followed by flow cytometry analysis using a FACSAria II.
[0045] 2. Results Figure 7 shows the results of immunostaining and observing CD31-positive cells on day 21 of culture. The image on the right is an enlarged image of the frame on the left. Spindle-shaped cells expanded and proliferated from the adipose tissue, gradually covering the entire periphery of the adipose tissue. Some of the cells were CD31-positive vascular endothelial cells. However, these vascular endothelial cells gradually decreased over the course of the culture. No vascular endothelial cell colonies were observed.
[0046] On day 21 of culture, the tissue and cells on the surface of the culture dish were dispersed into single cells and analyzed by flow cytometry. The results are shown in Figure 8. Most of the cells were CD44-positive mesenchymal cells, and the proportion of vascular endothelial cells (CD31-positive, CD45-negative) was less than 0.02%.
[0047] Example 2: Study of Wound Healing by Vascular Endothelial Cells Obtained by the Method of Example 1 In organ regeneration, tissue regeneration is impossible without the formation of blood vessels that transport oxygen and nutrients. In other words, enhancing angiogenesis improves blood flow, accelerates the supply of oxygen and nutrients, and promotes rapid tissue recovery. Conventional treatments have used bone marrow cells and mesenchymal stem cells for vascular regeneration. However, these cells lack the ability to contribute to vascularization, or only in very limited quantities. Therefore, treatments rely solely on the paracrine effect of angiogenesis-inducing substances secreted by the cells. In such treatments, neovascularization cannot be expected in patients with a low reserve capacity for angiogenesis. On the other hand, transplanting and establishing a vascular endothelial stem cell fraction capable of forming blood vessels in organs requiring vascular regeneration is expected to lead to more rapid organ regeneration. Therefore, we investigated whether the presence of vascular endothelial stem cells could induce angiogenesis and promote wound healing during wound healing in mice.
[0048] 1. Materials and Methods: KSN nude mice (Japan SLC Co., Ltd.) were used to transplant human vascular endothelial cells. A wound model was created by peeling off a 3 mm diameter section of skin, including the dermis, from the back of each mouse using a Derma Punch 3 mm (Maruho Co., Ltd.). Adipose tissue was cultured using the same method as in Example 1, and the polycarbonate membrane was excised from the Transwell insert. The adipose tissue and cells on the upper surface of the membrane were removed with a cotton swab, creating a sheet containing only endothelial cells, including vascular endothelial stem cells, remaining on the lower surface. This sheet was applied to the skin injury site, and a Tegaderm (3M Co., 1622W) sheet was applied over it for fixation and observation. The sheet was removed on day 5, and subsequent skin recovery was observed. Mice with the polycarbonate membrane of a Transwell insert without adipose tissue culture applied to the skin injury site served as controls.
[0049] For histological analysis, skin samples were collected from the injury site, fixed in 4% paraformaldehyde, and embedded in Tissue-Tec OCT compound (Sakura Finetech Japan) to prepare frozen blocks. The entire skin area was then sliced at 10 μm thickness. The sections were stained with hematoxylin and eosin using standard methods and subjected to histological analysis. To analyze the extent to which human adipose tissue-derived vascular endothelial cells contribute to angiogenesis in mouse skin tissue, immunostaining was performed. For immunostaining, rat anti-mouse CD31 antibody (clone MEC13.3, BD Biosciences) and rabbit anti-human CD31 antibody (clone EPR3094, Abcam) were used as primary antibodies, and Alexa Fluor 488-labeled goat anti-rat IgG (H+L) antibody (Invitrogen) and Alexa Fluor 546-labeled goat anti-rabbit IgG (H+L) antibody (Invitrogen) were used as secondary antibodies. Visualization was performed using a fluorescence microscope (DM5500B, Leica).
[0050] 2. Results Figure 9 (A) shows images of the back of a nude mouse immediately after skin removal and 7 days after application of a human adipose tissue-derived vascular endothelial cell sheet, and Figure 9 (B) shows the recovery rate of the skin injury site. In the control, 40% of the injury site was covered with skin. In contrast, 80% of the injury site to which the vascular endothelial cell sheet was applied was covered with skin, and the wound had healed.
[0051] The results of histological observations are shown in Figure 10. (A) shows the results for a control mouse, and (B) for a mouse with a vascular endothelial cell sheet attached (hereafter referred to as "cell sheet mouse"). The top row shows images stained with sorbitol and eosin, the middle row shows images immunostained with anti-mouse CD31 antibody, and the bottom row shows images immunostained with anti-human CD31 antibody. In the control mouse, a large number of inflammatory cells were present at the injury site ((A) upper dashed line), and epithelialization had not yet been completed. In contrast, in the cell sheet mouse, the area infiltrated by inflammatory cells was small ((B) upper dashed line), and epithelialization was also observed to have been completed. Furthermore, when observing vascular endothelial cells (CD31-positive cells) by immunostaining, only mouse blood vessels were observed in the control mouse, whereas human blood vessels were observed to have formed in the cell sheet mouse, indicating that skin damage had improved.
[0052] In this example, a sheet of vascular endothelial cells containing vascular endothelial stem cells on the underside of the porous membrane was applied to the site of skin injury, but it was confirmed in Example 1 that the cells recovered from the basement membrane matrix were vascular endothelial cells containing vascular endothelial stem cells, and it is clear that cells recovered from the basement membrane matrix can also be used for vascular regeneration. It is also possible to recover cells from the underside of the porous membrane and cells from the basement membrane matrix and use them for transplantation as dispersed cells that do not form a sheet.
[0053] Example 3: Organ culture of minced adipose tissue using a collagen membrane. 1. Materials and Methods (1) Culture of human adipose tissue. As in Example 1, human adipose tissue obtained by surgery was minced with scissors to prepare cubic minced tissue blocks approximately 2 mm on a side. A collagen membrane (trade name: Pernac, manufactured by Gunze Medical Co., Ltd.) was used as the porous membrane. Specifically, a cell strainer (manufactured by Falcon) was homemade by removing the mesh and attaching a collagen membrane to the underside. A cell strainer with a collagen membrane was inserted into a 6-well Costar cell culture multiwell plate (manufactured by Corning) to serve as a culture vessel. Thawed basement membrane matrix (Cultrex Basement Membrane Extract (BME), R&D) was supplemented with VEGF (PEPRO TECH) at a final concentration of 400 ng / mL. 2 mL of this solution was dispensed into each well of a 6-well plate and allowed to solidify at 37°C. 3 mL of Hu-Media EG2 (serum-free liquid medium for the growth of normal human vascular endothelial cells, Kurabo) was then added. Minced adipose tissue was placed on the collagen membrane of a cell strainer and inserted into each well of the 6-well plate. 1 mL of Hu-Media EG2 was added to the cell strainer, and the cells were cultured at 37°C in 5% CO2. The culture medium was replaced on days 6 and 12. On day 14 of culture, the cell strainer was harvested and immunostained.
[0054] (2) Immunostaining of cells beneath the membrane and observation of cells on the matrix. To detect endothelial cells beneath the collagen membrane, the collagen membrane was detached from the cell strainer and fixed with 4% paraformaldehyde. Immunostaining was performed using anti-CD31 antibody (clone WM59, BioLegend) and stained with diaminobenzidine (DAB, DOJINDO).
[0055] 2. Results Representative images of stained vascular endothelial cells (CD31-positive cells) on the underside of the collagen membrane are shown in Figure 11. Even when a collagen membrane was used as the porous membrane, CD31-positive vascular endothelial cells were observed to form colonies on the underside of the membrane.
[0056] The present invention is not limited to the above-described embodiments and examples, and various modifications are possible within the scope of the claims. The technical scope of the present invention also includes embodiments obtained by appropriately combining the technical means disclosed in different embodiments. Furthermore, all academic literature and patent documents described in this specification are incorporated herein by reference.
Claims
1. A method for producing a vascular endothelial cell population from a biological tissue or organ, comprising using a culture vessel having a structure in which a medium in a first culture vessel and a medium in a second culture vessel are in contact with each other via a porous membrane having pores for cell permeation, the culture surface of the first culture vessel being coated with an extracellular matrix containing a vascular endothelial cell migration factor, the method comprising filling the first and second culture vessels with culture medium, initiating culture of the biological tissue or organ in the second culture vessel, and recovering cells which have migrated into the first culture vessel through the porous membrane.
2. The method according to claim 1, wherein the purity of vascular endothelial cells in the vascular endothelial cell population is 50% or more.
3. The method according to claim 2, wherein the percentage of CD157-positive cells in the vascular endothelial cell population is 5% or more.
4. The method of claim 1, wherein the porous membrane is formed from a biocompatible material.
5. The method of claim 4, wherein the biocompatible material is selected from the group consisting of collagen, fibrin, hyaluronic acid, polylactic acid, polyglycolic acid, polycaprolactone, polydioxanone, trimethylene carbonate, polyethylene glycol, alginate, chitosan and mixtures thereof.
6. The method of claim 1, wherein the vascular endothelial cell migration factor is one or more selected from the group consisting of vascular endothelial growth factor, basic fibroblast growth factor, hepatocyte growth factor, epidermal growth factor, SDF-1, granulocyte-colony stimulating factor, leukemia inhibitory factor, nerve growth factor, platelet-derived growth factor, stem cell growth factor, axon repulsive factor, granulocyte-macrophage colony-stimulating factor, sphingosine-1-phosphate, angiopoietin, interleukin, CCL5, CCL1, placenta growth factor, apelin, elabella, netrin, semaphorin, gremlin, BafA, and serum.
7. The method according to claim 1, wherein the extracellular matrix is one or more selected from the group consisting of basement membrane matrix, laminin, type I collagen, type IV collagen, fibronectin, vitronectin, fibrin, tenascin, hyaluronic acid and proteoglycan.
8. A medicine comprising as an active ingredient a vascular endothelial cell population produced by the method according to any one of claims 1 to 7.
9. The pharmaceutical according to claim 8, which is for use in vascular regeneration, ameliorating ischemia, ameliorating malnutrition, treating vascular malformation, ameliorating blood flow insufficiency caused by vascular malformation, promoting organ regeneration, or treating diseases caused by abnormalities in molecules secreted from vascular endothelial cells.
10. A method for determining the angiogenic potential of a vascular endothelial cell population produced by the method according to any one of claims 1 to 7, comprising the steps of placing a second culture vessel having the porous membrane on its bottom surface on top of the first culture vessel to initiate culture, and, after the initiation of culture, observing the cells on the bottom surface of the lower culture vessel of the first culture vessel to determine that the obtained vascular endothelial cell population has angiogenic potential if a vascular network is formed.
11. A method for purifying vascular endothelial cells from biological tissue or organs, comprising using a culture vessel having a structure in which a culture medium in a first culture vessel and a culture medium in a second culture vessel are in contact with each other via a porous membrane having pores for cell permeation, the culture surface of the first culture vessel being coated with an extracellular matrix containing a vascular endothelial cell migration factor, the method comprising filling the first and second culture vessels with culture medium, initiating culture of the biological tissue or organ in the second culture vessel, and recovering cells which have migrated into the first culture vessel through the porous membrane.
12. The method according to claim 11, wherein the purity of vascular endothelial cells in the collected cells is 50% or more.
13. A method for growing vascular endothelial cells of a biological tissue or organ, comprising using a culture vessel having a structure in which a medium in a first culture vessel and a medium in a second culture vessel are in contact with each other via a porous membrane having pores for cell permeation, the culture surface of the first culture vessel being coated with an extracellular matrix containing a vascular endothelial cell migration factor, filling the first and second culture vessels with culture medium, and culturing the biological tissue or organ in the second culture vessel.
14. A method for producing a vascular endothelial cell sheet, comprising: using a culture vessel having a structure in which a culture medium in a first culture vessel and a culture medium in a second culture vessel are in contact with each other via a porous membrane having pores for cell permeation; the first culture vessel has a culture surface coated with an extracellular matrix containing a vascular endothelial cell migration factor; filling the first and second culture vessels with culture medium; initiating the culture of a biological tissue or organ in the second culture vessel; recovering the porous membrane; and removing the cells and tissue or organ present on the porous membrane on the second culture vessel side.
15. The method of claim 14, wherein said porous membrane is formed from a biocompatible material.
Citation Information
Patent Citations
useofapeptidethatinteractswithalphavbeta3integrinofendothelialcell
JP2006522111A
Scaffold for vascular endothelial cell migration
JP2013074936A
Angiogenesis promoter
JP2016216375A
Improved angiogenesis-inhibiting peptide and a composition for preventing and treating angiogenesis-related diseases containing the same as an active ingredient
JP2019503345A
Cell populations comprising CD31-positive, CD45-negative, CD200-positive mammalian cells, and use thereof
WO2019098264A1
